A Phase II, Double-Blind, Placebo-Controlled, Randomized Study Evaluating the Safety and Efficacy Of Carboplatin/Paclitaxel And Carboplatin/Paclitaxel/Bevacizumab With and Without GDC-0941 in Patients With Previously Untreated Advanced Or Recurrent Non-small Cell Lung Cancer.
Phase of Trial: Phase II
Latest Information Update: 29 Jan 2018
At a glance
- Drugs Pictrelisib (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Genentech
- 10 Jun 2017 Biomarkers information updated
- 31 May 2016 This trial is discontinued in Italy (end date:2016-03-30), Germany (End date:2015-05-28) and UK - MHRA (end date:2015-05-18) as per European Clinical Trials Database record.
- 04 May 2016 Status changed from active, no longer recruiting to completed.